Latest news for Embla Medical (OTC:OSSFF) Stock

Embla Medical hf is a provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park, creators of custom-built prosthetic solutions for people of all activity levels..

Embla Medical hf

<p>Financial giants have made a conspicuous bullish move on JPMorgan Chase. Our analysis of options history for JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) revealed 31 unusual trades.</p>
<p>Delving into the details, we found 48% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $429,963, and 20 were calls, valued at $1,022,321.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $225.0 for JPMorgan Chase over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for JPMorgan Chase options trades today is 2599.95 with a total volume of 7,714.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for JPMorgan Chase's big money trades within a strike price range of $160.0 to $225.0 over the last 30 days.</p>
<h3>JPMorgan Chase Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727295360_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$212.50</td>
<td>$78.0K</td>
<td>537</td>
<td>442</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$212.50</td>
<td>$73.0K</td>
<td>537</td>
<td>660</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$20.7</td>
<td>$20.65</td>
<td>$20.7</td>
<td>$195.00</td>
<td>$72.4K</td>
<td>3.5K</td>
<td>60</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.54</td>
<td>$212.50</td>
<td>$70.8K</td>
<td>537</td>
<td>1.1K</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$42.6</td>
<td>$42.2</td>
<td>$42.6</td>
<td>$180.00</td>
<td>$68.1K</td>
<td>716</td>
<td>21</td>
</tr>
</tbody>
</table>
</p>
<h3>About JPMorgan Chase</h3>
<p>JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4.1 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.</p>
<p>Following our analysis of the options activities associated with JPMorgan Chase, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of JPMorgan Chase</h3>
<ul>
<li>With a volume of 8,218,659, the price of JPM is down -0.66% at $210.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 16 days.</li>
</ul>
<h3>What The Experts Say On JPMorgan Chase</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $227.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on JPMorgan Chase, maintaining a target price of $220.<br />
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Hold, adjusting the price target to $235. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JPMorgan Chase with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

A Closer Look at JPMorgan Chase's Options Market Dynamics

News

Offerings

Hawaiian Electric Closes $558M Common Stock Offering At $9.25 Per Share To Fund Maui Wildfire Litigation Settlement; First $478M Payment Expected By Mid-2025

<p>Deep-pocketed investors have adopted a bearish approach towards Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RIVN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Rivian Automotive. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 21% leaning bullish and 71% bearish. Among these notable options, 8 are puts, totaling $798,541, and 6 are calls, amounting to $401,726.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $14.0 for Rivian Automotive during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Rivian Automotive's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rivian Automotive's whale activity within a strike price range from $5.0 to $14.0 in the last 30 days. </p>
<h3>Rivian Automotive 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727295355_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.2</td>
<td>$1.18</td>
<td>$1.19</td>
<td>$10.00</td>
<td>$476.0K</td>
<td>53.2K</td>
<td>4.8K</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.54</td>
<td>$0.53</td>
<td>$0.53</td>
<td>$14.00</td>
<td>$179.2K</td>
<td>1.1K</td>
<td>5.7K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$0.4</td>
<td>$0.39</td>
<td>$0.4</td>
<td>$11.50</td>
<td>$100.8K</td>
<td>5.0K</td>
<td>515</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.35</td>
<td>$7.3</td>
<td>$7.3</td>
<td>$5.00</td>
<td>$73.0K</td>
<td>242</td>
<td>108</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.22</td>
<td>$1.19</td>
<td>$1.19</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>53.2K</td>
<td>696</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rivian Automotive</h3>
<p>Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).</p>
<p>Having examined the options trading patterns of Rivian Automotive, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Rivian Automotive</h3>
<ul>
<li>With a volume of 50,692,485, the price of RIVN is down -6.76% at $11.04. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Rivian Automotive</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $17.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $19.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $19.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $19.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $19.<br />
&#x2A; An analyst from Morgan Stanley downgraded its action to Equal-Weight with a price target of $13. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rivian Automotive with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RIVN

Rivian Automotive Unusual Options Activity For September 25

<p>Financial giants have made a conspicuous bearish move on UiPath. Our analysis of options history for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 18% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $666,810, and 5 were calls, valued at $225,186.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $12.5 for UiPath during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UiPath's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UiPath's substantial trades, within a strike price spectrum from $10.0 to $12.5 over the preceding 30 days.</p>
<h3>UiPath Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727295350_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.65</td>
<td>$1.6</td>
<td>$1.65</td>
<td>$12.00</td>
<td>$445.7K</td>
<td>8.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$10.00</td>
<td>$69.2K</td>
<td>0</td>
<td>188</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$64.0K</td>
<td>8.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.2</td>
<td>$4.6</td>
<td>$10.00</td>
<td>$50.5K</td>
<td>1.7K</td>
<td>165</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$48.0K</td>
<td>8.4K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About UiPath</h3>
<p>UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.</p>
<p>Having examined the options trading patterns of UiPath, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of UiPath</h3>
<ul>
<li>With a volume of 5,485,144, the price of PATH is down -3.63% at $12.48. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 65 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for UiPath, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PATH

Unpacking the Latest Options Trading Trends in UiPath

WIIM

TBIO

Telesis Bio Partners shares are trading higher after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.

<p>- SEC Filingwrite as one headline based on&nbsp;</p>


AMTB

Amerant Bancorp Files For Common Stock Offering Of Up To $150M

<p><strong>Intel Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading higher Wednesday following the company's highly anticipated launch of its Xeon 6 processors and Gaudi 3 AI accelerators. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/09/41006101/jump-on-intel-now-qualcomms-bid-could-ignite-a-rally">what you need to know.</a></p>
<p><strong>What To Know:</strong> These next-generation products are designed to power high-performance AI and computing workloads, with Xeon 6 doubling the performance of its predecessor and Gaudi 3 delivering up to 20% more throughput compared to Nvidia's H100, particularly in large-scale AI model training and inference.</p>
<p>Through key partnerships with Dell Technologies and IBM, Intel is pushing for co-engineered AI systems that deliver better performance per watt and lower total cost of ownership for enterprise AI deployments. </p>
<p>The Gaudi 3 AI accelerator, specifically optimized for AI models like LLaMa 2, along with Xeon 6, is expected to make Intel a more competitive player in the enterprise AI ecosystem.</p>
<p><strong>INTC Price Action</strong>: Intel's stock was up by 3.20% at $23.54 at market close Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25160053/INTC-3-1024x542.png" alt="" class="wp-image-566410" style="width:516px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25160053/INTC-3-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25160053/INTC-3-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25160053/INTC-3-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25160053/INTC-3.png 1377w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>See Also:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/politics/24/09/41033980/trumps-tariff-threat-could-hit-john-deere-stock-pro-trump-congress-member-faces-potential-losses">Trump&#8217;s Tariff Threat Could Hit John Deere Stock: Pro-Trump Congress Member Faces Potential Losses</a></strong></li>
</ul>
<p><em>Photo: Tada Images/Shutterstock.com</em>.</p>


Movers

Tech

INTC

Why Are Intel Shares Trading Higher Today?

Management

MSFT

OpenAI To Remove Non-Profit Control And Give Sam Altman Equity

H.B. Fuller shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 adjusted EPS guidance below estimates.

<p>Guo Previously Served As Financial Reporting Manager At Company Subsidiary</p>
<p>- SEC Filing</p>


Haoxi Health Technology Ltd Announces CFO Change As Bo Lv Resigns For Personal Reasons; Board Appoints Yu Guo As New CFO Effective September 25, 2024, With A One-Year Term

<p>Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.60 by 6.67 percent. This is a 55.56 percent decrease over earnings of $1.26 per share from the same period last year.  The company reported quarterly sales of $834.00 million which beat the analyst consensus estimate of $757.10 million by 10.16 percent.  This is a 7.93 percent decrease over sales of $905.80 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Worthington Steel Q1 Adj $0.56 Misses $0.60 Estimate, Sales $834.00M Beat $757.10M Estimate

InvenTrust Properties Corp Issues 9.2M Shares Of Common Stock In Public Offering, Raising Approximately $246.3M In Net Proceeds

<p>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>), a global technology and services leader, today announced the release of iX Hello, a GenAI-powered self-service application designed to supercharge productivity and engagement quality, with high security.&nbsp;&nbsp;</p>
<p>iX Hello offers an out-of-the box solution for businesses to create virtual assistants for countless use cases — from data analysis to rapid language translations to internal self-service chatbots and more. The product acts as an assistant that securely integrates with leading Large Language Models (LLMs) as well as internal data sources, to cost-effectively boost productivity and quality of work within an on-brand, compliant, and secure environment.</p>


CNXC

Concentrix  Announced The Release Of iX Hello, A GenAI-Powered Self-Service Application Designed To Supercharge Productivity And Engagement Quality, With High Security

<p>A <strong>Walt Disney Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) analyst says the company's momentum in box office blockbusters and streaming growth can help offset Experiences and linear weakness when the company reports fourth-quarter financial<a href="https://www.benzinga.com/earnings"> results in November.</a></p>
<p><strong>The Disney Analyst</strong>: Goldman Sachs analyst Michael Ng reiterated a Buy rating on Disney and lowered the price target from $124 to $120.</p>
<p><strong>The Analyst Takeaways</strong>: Disney's fourth-quarter financial results could see strong subscriber growth for streaming and box office strength, likely offsetting headwinds of Experiences and the DirecTV blackout, Ng said in a new investor note.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/08/40218880/disneys-q3-earnings-revenue-and-eps-beat-streaming-business-turns-profitable-strong-espn-revenue-bo">Disney&#8217;s Q3 Earnings: Revenue And EPS Beat, Streaming Business Turns Profitable, Strong ESPN Revenue Boost</a></strong></p>
<p>"The subscriber momentum and recent price increases should put Direct-to-Consumer on track for continued revenue and profit growth," Ng said.</p>
<p>The analyst highlighted Disney+ bundles, promotional offers and the streaming premiere of "Inside Out 2" on the platform on Sept. 25 as catalysts that could increase subscribers. "Inside Out 2,&#8221; the <a href="https://www.benzinga.com/general/entertainment/24/06/39464286/disney-shareholders-could-experience-joy-as-inside-out-2-crushes-box-office-nears-1b-milest">highest grossing animated film</a> of all time, will help the box office segment, the analyst added.</p>
<p>Ng forecasts Disney adding 3.5 million net core Disney+ subscribers in the quarter compared to consensus estimates of 1.8 million.</p>
<p>Potential negatives in the quarter include the Experiences segment and the two-week blackout of Disney channels on DirecTV. The analyst sees a potential $90 million headwind to affiliate fees from <a href="https://www.benzinga.com/general/entertainment/24/09/40670016/disney-and-directv-fail-to-reach-deal-over-11m-subscribers-face-blackout-ahead-of-nfl-seaso">the DirecTV blackout.</a></p>
<p>Ng is forecasting Disney to have fourth-quarter earnings of $1.16. The consensus Street estimate is $1.09 according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092524&amp;t=be2bearmibe3na1">from Benzinga Pro. </a>The company has beat earnings estimates from analysts in five straight quarter.</p>
<p>The analyst forecasts fourth-quarter revenue of $22.47, compared to a consensus Street estimate of $22.29 billion. The company has missed revenue estimates from analysts in four of the last five quarters.</p>
<p>Ng's price target of $120 is based on a sum-of-the-parts valuation of Disney with multiples applied to the company's Parks and Experiences, Consumer Products, Linear Networks, Content Sales and Licensing, Sports and DTC business lines.</p>
<p><strong>Price Action: </strong>Disney shares trade at $93.92 Wednesday versus a 52-week trading range of $78.73 to $123.74. Disney stock is up 4% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946689/disney-faces-more-change-ahead-as-espn-dtc-launch-will-accelerate-cord-cutting-nba-">Disney Faces &#8216;More Change Ahead&#8217; As ESPN DTC Launch Will Accelerate Cord Cutting: NBA Rights, College Football Offer Upside, Analyst Says</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Entertainment

Price Target

Reiteration

Analyst Ratings

Trading Ideas

Disney Stock Could Benefit From Box Office Strength, Streaming: Analyst Says DTC Set 'For Continued Revenue And Profit Growth'

Concentrix shares are trading lower following mixed Q3 financial results.

Macro Notification

General

VP Harris Says I Will Never Hesitate To Take Swift Measures When China Undermines Trade Rules Of The Road, Including On Steel

Biotech

QGEN

QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples

<p><a href="https://www.globenewswire.com/Tracker?data=kvTB518CkLmUMRynkspjr4LvB4adD-Ge9H_Mxuec_hlDix5tmrntN43wRIBhJOi1GJ9fvqDeIz7F2JZiG20ypkigDetlPY3XOllbHmRyX20=">Lumos Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUMO#NASDAQ">LUMO</a>), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the <a href="https://www.globenewswire.com/Tracker?data=zfecdTl8-odtcssg4HGxOmHI0xEgwtKo9M8eLvZZlxDW3D69qFISUj70W0GFbSJZpAICvhKPoSVhE5kSYDKqMZ3iniI4KSaAlYT0dgEsFhqDAMIU4VPmuOhsOfolSjPpiNDtOuu7mpz9zBZVNIwrNSHcrlfWdh3qfbWwYwsyXPA=">13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society</a>, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by <a href="https://www.globenewswire.com/Tracker?data=Q_43KNH2BJaBlOIH1Jc9rp4SmwZo-8WPqvbOpN7c1UfV_KzWTkEBAvKT2XLdRMMbd_iMp7zXuYDXT3CBXYeSUVPJlG-UDSyKVcw1CU84rEYpSIahiOzGwZj5fCFBNABI">Professor Paul Hofman, MD</a>, Liggins Institute, University of Auckland, Auckland, New Zealand.<br /><br />&nbsp;</p>
<p><strong>Abstract Presentation: Thursday, October 3rd – Oral Session: Growth &amp; Puberty – 2:30PM Local Time</strong></p>
<ul>
<li>Abstract entitled,<i> Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial</i> (Paul Hofman, MD, <i>et al</i>)</li>
</ul>


LUMO

Lumos Pharma Announces Abstract Accepted For Oral Presentation At The 13th Biennial Scientific Meeting Of The Asia Pacific Pediatric Endocrine Society, APPES 2024

Guidance

Concentrix Sees Q4 Revenue at $2.42B-$2.47B, Adj. EPS $2.90-$3.16; Sees FY24 Revenue $9.591B-$9.641B, Adj. EPS $11.05-$11.31

<p>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) reported quarterly losses of $(0.37) per share. This is a 516.67 percent decrease over losses of $(0.06) per share from the same period last year.  The company reported $4.83 million in sales this quarter. This is a 67.27 percent decrease over sales of $14.75 million the same period last year.</p>


LAES

SEALSQ H1 EPS $(0.37) Down From $(0.06) YoY, Sales $4.83M Down From $14.75M YoY

Press Releases

Embla Medical hf: Interim Report Q2 2024

Para Athletes Using Össur Mobility Solutions Win 22 Medals in Paris

OSSFF

Embla Medical

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Embla Medical

News

Latest news for Embla Medical (OTC:OSSFF) Stock